# Franklin Genomic Advancements ETF (HELX): ETF Facts & Distributions > Markdown mirror of https://www.dividenddata.com/funds/helx for AI agents. Same live data as the HTML page, regenerated on the same refresh cycle. Not investment advice. - Issuer: Franklin Templeton · Asset class: Equity - Strategy: Thematic · Inception: 2020-02-25 This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for b... ## Key Facts | Metric | Value | |---|---| | Price | $42.69 | | Expense Ratio | 0.50% | | Assets Under Management | $34.2M | | NAV | $42.71 | | Holdings Count | 63 | | Distribution Yield (TTM) | — | | Annual Distribution (TTM) | — /share | | Distribution Frequency | Irregular | | 52-Week Range | $31.24 – $45.58 | | Beta | 0.96 | ## Latest Distribution - Amount: $0.1433 /share - Ex-date: 2025-12-30 - Pay date: 2026-01-08 ## Frequently Asked Questions ### What does HELX invest in? This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations. ### What is the expense ratio of HELX? Franklin Genomic Advancements ETF (HELX) charges an expense ratio of 0.50%. This is the annual fee deducted from fund assets to cover management and operations. ### How big is HELX? Franklin Genomic Advancements ETF (HELX) manages $34.2M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure. Funds below ~$50M are at higher risk of liquidation. ### Is HELX actively managed or an index fund? HELX's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy. ### When was HELX launched? Franklin Genomic Advancements ETF (HELX) launched in February 2020 and is managed by Franklin Templeton. ### How has HELX performed? HELX's total return (price change plus reinvested distributions) is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon. ### Does HELX pay a dividend? Franklin Genomic Advancements ETF (HELX) currently distributes little or no income. Trailing-twelve-month yield is —. Investors looking for income should consider income-focused alternatives. See the Peers tab. ### How often does HELX pay dividends? Franklin Genomic Advancements ETF pays dividends Irregular. Each ex-dividend date, record date, and payment date is listed in the dividend history table on this page. ### What is HELX's dividend yield? HELX's trailing-twelve-month yield is —, calculated from the sum of dividends over the past year divided by the current price. ### When is HELX's next ex-dividend date? The most recently announced ex-dividend date for HELX was 2025-12-30. The next ex-date typically follows Irregular; once announced it appears at the top of the dividend history table on this page. ### How much will HELX's expense ratio cost me over 30 years? On a $10,000 investment compounding at 7% gross return, a 0.50% expense ratio quietly compounds against your balance every year. The Fee Compounding Forecast card above projects the dollar drag for any holding period and assumption you pick. The typical result for a 1.0% expense ratio on a 30-year hold is roughly 25% of the final balance lost to fees. ### How does HELX charge its expense ratio? The expense ratio is deducted in tiny daily slices from HELX's net asset value (NAV). You never see a bill. The price quoted on every exchange is already net of fees. There's no "fee day" to avoid; the cost is continuous and built into the trading price. ### Why does HELX cost more than a fund like VOO? HELX's strategy (current expense ratio 0.50%) is different from a broad-market index tracker like VOO, so its fee belongs to a different cohort. The Cost Verdict card above shows you where HELX sits within its own category, which is the comparison that actually matters. ### Are there cheaper alternatives to HELX? The Lower-Fee Alternatives card above lists ETFs following the same investment strategy as HELX (0.50%) but at a lower expense ratio. Each row shows the fee gap, the peer's AUM as a liquidity sanity-check, and a direct link to that fund's analysis page. Cheaper price doesn't automatically mean better. Verify the peer holds what you actually want. ## More on Dividend Data - Overview (HTML): https://www.dividenddata.com/funds/helx - Distribution history: https://www.dividenddata.com/funds/helx/dividend - Holdings & diversification: https://www.dividenddata.com/funds/helx/diversification - Fees & cheaper alternatives: https://www.dividenddata.com/funds/helx/expenses - Peer comparison: https://www.dividenddata.com/funds/helx/peers Data sourced from primary filings and market data providers; see https://www.dividenddata.com/methodology.